Ramón
García Sanz
Profesor Titular de Universidad
Hospital Ramón y Cajal
Madrid, EspañaPublicaciones en colaboración con investigadores/as de Hospital Ramón y Cajal (34)
2023
-
Comparison of the 2022 and 2017 European LeukemiaNet risk classifications in a real-life cohort of the PETHEMA group
Blood Cancer Journal, Vol. 13, Núm. 1
-
Expert consensus on the integrated diagnosis of idiopathic multicentric Castleman disease
Revista Espanola de Patologia, Vol. 56, Núm. 3, pp. 158-167
-
Impact of the COVID-19 pandemic on the diagnosis and treatment of onco-hematologic patients: a discussion paper
Revista Espanola de Quimioterapia, Vol. 36, Núm. 1, pp. 1-25
-
Molecular Landscape and Validation of New Genomic Classification in 2668 Adult AML Patients: Real Life Data from the PETHEMA Registry
Cancers, Vol. 15, Núm. 2
2022
-
A simple score to predict early severe infections in patients with newly diagnosed multiple myeloma
Blood cancer journal, Vol. 12, Núm. 4, pp. 68
-
Applicability of probabilistic graphical models for early detection of SARS-CoV-2 reactive antibodies after SARS-CoV-2 vaccination in hematological patients
Annals of Hematology, Vol. 101, Núm. 9, pp. 2053-2067
-
Booster effect after SARS-CoV-2 vaccination in immunocompromised hematology patients with prior COVID-19
Blood Advances
-
Ibrutinib in Combination With Rituximab for Indolent Clinical Forms of Mantle Cell Lymphoma (IMCL-2015): A Multicenter, Open-Label, Single-Arm, Phase II Trial
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 40, Núm. 11, pp. 1196-1205
-
Impact of FLT3–ITD Mutation Status and Its Ratio in a Cohort of 2901 Patients Undergoing Upfront Intensive Chemotherapy: A PETHEMA Registry Study
Cancers, Vol. 14, Núm. 23
-
NGS-Based Molecular Karyotyping of Multiple Myeloma: Results from the GEM12 Clinical Trial
Cancers, Vol. 14, Núm. 20
-
Spanish Society of Hematology and Hemotherapy expert consensus opinion for SARS-CoV-2 vaccination in onco-hematological patients
Leukemia and Lymphoma, Vol. 63, Núm. 3, pp. 538-550
2021
-
Impact of the COVID-19 pandemic on the care of cancer patients in Spain
ESMO open, Vol. 6, Núm. 3, pp. 100157
2020
-
Measurable Residual Disease by Next-Generation Flow Cytometry in Multiple Myeloma
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 38, Núm. 8, pp. 784-792
-
Networking for advanced molecular diagnosis in acute myeloid leukemia patients is possible: the PETHEMA NGS-AML project
Haematologica, Vol. Online ahead of print
-
Pembrolizumab as consolidation strategy in patients with multiple myeloma: Results of the GEM-pembresid clinical trial
Cancers, Vol. 12, Núm. 12, pp. 1-13
-
Potential Survival Benefit for Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation after Nivolumab Therapy for Relapse/Refractory Hodgkin Lymphoma: Real-Life Experience in Spain
Biology of Blood and Marrow Transplantation, Vol. 26, Núm. 8, pp. 1534-1542
2019
-
Atrial Fibrillation in Active Cancer Patients: Expert Position Paper and Recommendations
Revista Espanola de Cardiologia, Vol. 72, Núm. 9, pp. 749-759
-
Brentuximab vedotin and ESHAP is highly effective as second-line therapy for Hodgkin lymphoma patients (long-term results of a trial by the Spanish GELTAMO Group)
Annals of Oncology, Vol. 30, Núm. 4, pp. 612-620
2017
-
Cardio-Onco-Hematology in Clinical Practice. Position Paper and Recommendations
Revista Espanola de Cardiologia, Vol. 70, Núm. 6, pp. 474-486
-
Comorbidities, not age, are predictive of survival after autologous hematopoietic cell transplantation for relapsed/refractory Hodgkin’s lymphoma in patients older than 50 years
Annals of Hematology, Vol. 96, Núm. 1, pp. 9-16